Introducing...DonorPlex^TM Pooled Donor Human Hepatocytes for Robust and Consistent Results 

Using pooled donor human hepatocyte lots in your ADME studies that ensure robust and consistent results are of great importance. With our new proprietary algorithm we are able to predict yield, viability, and functional phenotype of DonorPlex^TM Primary Human Hepatocytes which in turn will support more consistent results in your ADME studies.What is more, with our large inventory of single donor human hepatocyte lots and this unique algorithm, we can also produce a variety of different phenotypes to fit your needs.

Watch as Dr. Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza, introduces our new DonorPlex^TM Pooled Human Hepatocytes as a valuable solution for pharma companies during the 2019 SLAS Conference.

We have optimized a robust manufacturing process to produce pooled donor human hepatocyte lots with little variability. Demonstrated in Figure 1, we show ability to reproducibly create a lot with the same phenotype on multiple different dates. The optimized manufacturing process also ensures each lot of pooled suspension hepatocytes meet stringent yield and viability specifications.

With our optimized pooling procedure, we can provide our customers with a variety of pool demographics and sizes for their metabolism testing needs. With our predictive algorithm, we can also create customer-driven customizable pooled donor human hepatocyte lots to meet specific CYP activity requirements.